Video

Dr. Syan on her clinical experience with implantable SNM treatment for bladder/bowel dysfunction

Author(s):

Urology Times staff
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Raveen Syan, MD, discusses her clinical experience with sacral neuromodulation implantable neurostimulator treatment for patients with bladder and bowel dysfunction. Syan is an assistant professor of Clinical Urology at the Desai Sethi Urology Institute at the University of Miami Miller School of Medicine.

      Related Videos
      Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © - bongkarn - stock.adobe.com
      Experts discuss expanding use of vibegron for OAB
      Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
      Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
      Karyn S. Eilber, MD, answers a question during a Zoom video interview
      Karyn S. Eilber, MD, on patient counseling for onabotA treatment for OAB
      Woman at doctor | Image Credit: © rocketclips - stock.adobe.com
      Optimizing onabotA for OAB: What are some common misconceptions?
      Closeup of patient with prescription | Image Credit: © gpointstudio - stock.adobe.com
      Investigators characterize vibegron prescribing patterns for OAB
      Colin Goudelocke, MD, answers a question during a Zoom video interview
      Expert outlines advantages of batteryless sacral neuromodulation device
      Emmanuel Chartier-Kastler, MD, shares initial data on UroActive System in women with SUI
      Emmanuel Chartier-Kastler, MD, shares initial data on UroActive System in women with SUI
      Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
      Smaller size, patient control advantages of neurostimulator for OAB
      Batteryless neurostimulator found efficacious at 6-month follow-up
      Batteryless neurostimulator found efficacious at 6-month follow-up
      Colin Goudelocke, MD, answers a question during a Zoom video interview
      Colin Goudelocke, MD, on 6-month data for batteryless neurostimulator
      Related Content
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      May 1st 2025

      Safety, efficacy of vibegron sustained in men with OAB treated for BPH

      Benjamin P. Saylor
      The investigators reported an overall incidence of AEs of 29.6%.
      Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
      March 21st 2022

      Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

      Urology Times staff
      “This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
      Neuromodulation device shows promising efficacy for neurogenic bladder
      April 16th 2025

      Neuromodulation device shows promising efficacy for neurogenic bladder

      Hannah Clarke
      Data from the pivotal CONTINENCE trial showed encouraging efficacy of SCONE neuromodulation therapy.
      Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
      March 18th 2022

      Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

      Urology Times staff
      “We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
      Faceless view of senior man talking to doctor in bright light while taking notes on clipboard | Image Credit: © DragonImages - stock.adobe.com
      April 3rd 2025

      Kiran Sury, MD, on implementing ProACT for incontinence

      Kiran Sury, MD
      "In terms of making it a safe, highly reliable operation, if you're comfortable with slings and sphincters, you are very well positioned to learn this surger," says Kiran Sury, MD.
      FDA grants 510(k) clearance to Glean Urodynamics System
      April 2nd 2025

      FDA grants 510(k) clearance to Glean Urodynamics System

      Hannah Clarke
      "Glean will enable patients to void naturally, without catheters in place. I believe this advance will yield a better test that mimics actual symptoms," says Bilal I. Chughtai, MD.
      © 2025 MJH Life Sciences

      All rights reserved.